Treatment of malignancy by direct gene transfer of a foreign MHC class I molecule

Cancer Immunology Immunotherapy

Volumn 43, Issue 3, 1996, Pages 180-189

  DeBruyne, Lisa ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

gene transfer; MHC class I; T cells; V

Indexed keywords

CD8 ANTIGEN; CYTOKINE; DNA; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GENE TRANSFER; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CLINICAL TRIALS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B7 ANTIGEN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029987510     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050320     Document Type: Conference Paper

References (107)

1. Allison JP (1994) CD28-B7 interactions in T-cell activation. Curr Opin Immunol 6: 414
2. Aruga A, Shu S, Chang AE (1995) Tumor-specific GM-CSF and IFN gamma secretion is associated with in vivo therapeutic efficacy of activated tumordraining lymph node cells. Cancer Immunol Immunother 41: 317
3. + T cell-mediated immunity. J Exp Med 168: 2193
4. + suppressor-inducer T cells. J Immunol 145: 2854
5. + tumor-infiltrating lymphocytes. J Exp Med 173: 647
6. Bennett WT, Pandolfi F, Grove BH, Hawes GE, Boyle LA, Kradin RL, Kurnick JT (1992) Dominant rearrangements among human tumor-infiltrating lymphocytes. Analysis of T cells derived from 32 patients with melanoma, lung and renal cell carcinoma. Cancer 69: 2379
7. Berns AJ, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffe EM, Lazenby AJ, Levitsky HI, Marshall FF, Mulligan RC, Nelson WG, Owens AH, Pardoll DM, Parry G, Partin AH, Piantadosi S, Simons JW, Zabora JR (1995) Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6: 347
8. Bishop DK, Ferguson RM, Orosz CG (1990) Differential distribution of antigen-specific helper T cells and cytotoxic T cells after antigenic stimulation in vivo. J Immunol 144: 1153
9. Caignard A, Dietrich PY, Morand B, Lim A, Pannetier C, Leridant AM, Hercend T, Even J, Kourilsky P, Triebel F (1994) Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. Cancer Res 54: 1292
10. Cascinelli N, Foa R, Parmiani G, Arienti F, Belli F, Bernengo MG, Clemente C, Colombo MP, Guarini A, Illeni MT, Masheroni L, Melani C, Prada A, Sule-Suso J (1994) Active immunization of metastatic melanoma patients with IL-4 transduced, allogeneic melanoma cells. Hum Gene Ther 5: 1059
11. Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 145: 2359
12. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71: 1093
13. Chou T, Chang AE, Shu S (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologie specificity. J Immunol 140: 2453
14. Clark SC, Kamen R (1987) The human hematopoietic colony-stimulating factors. Science 236: 1229
15. DeBruyne LA, Chang AE, Cameron MJ, Yang ZY, Gordon D, Nabel EG, Nabel GJ, Bishop DK (1996) Direct transfer of a foreign MHC gene into human melanoma alters T cell receptor Vβ usage by tumor infiltrating lymphocytes. Cancer Immunol Immunother 43: 49
16. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539
17. D'Urso CM, Wang Z, Cao Y, Tatake R, Zeff RA, Ferrone S (1991) Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2m gene expression. J Clin Invest 87: 284
18. Farrar MA, Schreiber RD (1993) The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11: 571
19. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Volgelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397
20. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL (1994) Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 269: 2550
21. Felgner PL, Padek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413
22. Fenton RT, Sznol M, Luster DG, Taub DD, Longo DL (1995) A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-Al in patients with stage IV melanoma. Hum Gene Ther 6: 87
23. Ferradini L, Roman-Roman S, Azocar J, Avril MF, Viel S, Triebel F, Hercend T (1992) Analysis of T-cell receptor α/β variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res 52: 4649
24. Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T (1993) Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma: evidence for in situ T cell clonal expansion. J Clin Invest 91: 1183
25. Ferrone S, Marincola FM (1995) Loss of HLA class I antigen by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16: 487
26. Floutsis G, Ulsh L, Ladisch S (1989) Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int J Cancer 43: 6
27. Gansbacher B, Houghton A, Livingston P, Minasian L, Rosenthal F, Gilboa E, Golde D, Oettgen H, Steffens T, Yang SY, Wong G (1992) A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Hum Gene Ther 3: 677
28. Gansbacher B, Motzer R, Houghton A, Gilboa E, Bander N, Golde D, Minasian L, Gastl G, Rosenthal F, Scheinfeld J, Yang SY, Wong G, Reuter V, Livingston P, Bosl G, Nanus D, Fair WR (1992) A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther 3: 691
29. Gao X, Huang L (1991) A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 179: 280
30. Gilboa E, Lyerly HK, Vieweg J, Saito S (1994) Immunotherapy of cancer using cytokine gene-modified tumor vaccines. Semin Cancer Biol 5: 409
31. Goedegebuure PS, Zuber M, Leonard-Vidal L, Burger UL, Cusak JC Jr, Chang MP, Douville LM, Eberlein TJ (1994) Reactivation of murine tumor-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 3: 79
32. German C, Padmanabhan R, Howard BH (1983) High efficiency DNA-mediated transformation of primate cells. Science 221: 551
33. Halapi E, Yamamoto Y, Juhlin C, Jeddi-Tehrani M, Grunewald J, Andersson R, Hising C, Masucci G, Mellstedt H, Kiessling R (1993) Restricted T cell receptor V-β and J-β usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunol Immunother 36: 191
34. Hammerling GJ, Klar D, Katzav S, Segal S, Feldman M, Wallich R, Hammerling A (1985) Manipulation of metastasis and tumour growth by transfection with histocompatibility class I genes. J Immunogenet 13: 153
35. Hersh EM, Akporiaye E, Harris D, Stopek AT, Unger EC, Warneke JA (1994) Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Hum Gene Ther 5: 1371
36. Holden CA, Sadisen AR, McDonald DM (1983) Absence of human leukocyte antigen molecules in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J Am Acad Dermatol 9: 867
37. Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311: 750
38. Isakov N, Katza S, Feldman M, Segal S (1983) Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis lung carcinoma cells and its relevance to the tumor's metastatic properties. J Natl Cancer Inst 71: 139
39. Johnson CS, Chang MJ, Thurlow SM, Pourbohloul SC, Furmanski P (1990) Immunotherapeutic approaches to leukemia: the use of the Friend virus-induced erythroleukemia model system. Cancer Res 50: 5682
40. June CH, Bluestone JA, Nadler LM, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15: 321
41. Kawakami Y, Nishimura MI, Restifo NP, Topalian SL, O'Neil BH, Shilyansky J, Yannelli JR, Rosenberg SA (1993) T-cell recognition of human melanoma antigens. J Immunother 14: 88
42. Keilholz U, Scheibenbogen C, Stoelben E, Saeger HD, Hunstein W (1994) Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer 30A: 955
43. Klein J, Juretic A, Baxevanis CN, Nagy ZA (1981) The traditional and a new version of the mouse H-2 complex. Nature 291: 455
44. Kradin RL, Lazarus DS, Dubinett SM (1989) Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet I: 577
45. Kruit WH, Goey SH, Calabresi F, Lindemann A, Stahel RA, Poliwoda H, Osterwalder B, Stoter G (1995) Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma. Br J Cancer 71: 1319
46. Lindahl P, Leary P, Gresser I (1973) Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells. Proc Natl Acad Sci USA 70: 2785
47. Lindahl P, Gresser I, Leary P, Tovey M (1976) Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells. Proc Natl Acad Sci USA 73: 1284
48. Ljunggren H-G, Karre K (1986) Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? J Immunogenet 13: 141
49. Lotze MT, Grum EA, Mazumdo A, Strausser L, Rosenberg SA (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420
50. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T (1993) Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res 53: 3569
51. Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rose-John S (1995) Gene therapy of human melanoma: immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting IL-6 and soluble IL-6 receptor. Hum Gene Ther 6: 805
52. Matzinger P, Bevan MJ (1977) Why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 29: 1
53. Melani C, Chiodoni C, Arienti F, Maccalli C, Sule-Suso J, Anichini A, Colombo MP, Parmiani G (1994) Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells. Nat Immun 13: 76
54. Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S (1994) Increased effectiveness of interferon α-2β following active specific immunotherapy for melanoma. J Clin Oncol 12: 402
55. Morton DL, Eilber FR, Holmes EC (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180: 635
56. Moss PAH, Rosenberg WMC, Bell JI (1992) The human T cell receptor in health and disease. Annu Rev Immunol 10: 71
57. Mule JJ, Krosnick A, Rosenberg SA (1989) IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. J Immunol 142: 726
58. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ (1989) Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244: 1342
59. Nabel EG, Plautz G, Nabel GJ (1990) Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 249: 1285
60. Nabel EG, Gordon D, Yang Z, Xu E, San H, Plautz GK, Wu BY, Gao X, Huang E, Nabel GJ (1992) Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 3: 649
61. Nabel EG, Plautz G, Nabel GJ (1992) Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci USA 89: 5157
62. Nabel EG, Yang ZY, Plautz, G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ (1993) Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 362: 844
63. Nabel GJ, Chang A, Nabel EG, Plautz G, Fox BA, Huang E, Shu S (1992) Clinical protocol: immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3: 399
64. Nabel GJ, Nabel EG, Yang Z-Y, Fox BA, Plautz GE, Gao X, Huang E, Shu S, Gordon D, Chang AE (1993) Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 90: 11 307
65. Nabel GJ, Chang AE, Nabel EG, Plautz GE, Ensminger W, Fox BA, Felgner P, Shu S, Cho K (1994) Clinical protocol: immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 5: 57
66. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE (1996) Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA
67. Old LJ (1985) Tumor necrosis factor (TNF). Science 230: 630
68. Old LJ (1987) Tumour necrosis factor. Polypeptide mediator network. Nature 326: 330
69. O'Mahony AM, O'Sullivan GC, O'Connell J, Cotter TG, Collins JK (1993) An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 151: 4847
70. Osanto S, Brouwenstyn N, Vassen N, Figdor CG, Melief CJM, Schrier PI (1993) Immunization with IE-2 transfected melanoma cells. Hum Gene Ther 4: 323
71. Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ (1993) T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 151: 5472
72. Plautz GE, Yang Z, Wu B, Gao X, Huang E, Nabel GJ (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90: 4645
73. Poppema S, Brocker EB, De Leij E, Terbrack D, Visscher T, ter Harr A, Macher E, The TH, Sorg C (1983) In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 51: 77
74. Powell MB, Conta BS, Horowitz M, Ruddle H (1985) The differential inhibitory effect of lymphotoxin and immune interferon on normal and malignant lymphoid cells. Lymphokine Res 4: 13
75. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P (1994) Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 153: 2807
76. Restifo NP, Esquivel F, Kawakumi Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177: 265
77. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 14: 182
78. Rosenberg SA (1992) Immunization of cancer patients using autologous cancer cell modified by insertion of the gene for tumor necrosis factor. Hum Gene Ther 3: 57
79. Rosenberg SA, Mule JJ, Spiess PJ (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169
80. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676
81. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474
82. Rosenberg SA, Abersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF (1990) Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570
83. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907
84. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86: 1159
85. Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12: 370
86. San H, Yang Z, Pompili VJ, Jaffe ML, Plautz GE, Xu L, et al (1993) Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 4: 781
87. Schmidt-Wolf IGH, Hugh D, Neubauer A, Wittig B (1994) 1L-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum Gene Ther 5: 1161
88. Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR. Steinberg SM, Rosenberg SA, Topalian SL (1994) In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 12: 1475
89. Seigler HF, Darrow TL, Abdel-Wahab Z, Gangavalli R, Barber J (1994) A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma. Hum Gene Ther 5: 761
90. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A (1993) T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR β chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 178: 1231
91. Shoskes DA, Wood KJ (1994) Indirect presentation of MHC antigens in transplantation. Immunol Today 15: 32
92. Shu S, Rosenberg SA (1985) Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 45: 1657
93. Skoskiewicz MJ, Colvin RB, Schneeberger EE, Russell PS (1985) Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J Exp Med 162: 1645
94. Spiess PJ, Yang JC, Rosenberg SA (1987) In vivo antitumor activity of tumorinfiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067
95. Straten PT, Scholler J, Hou-Jensen K, Zeuthen J (1994) Perferential usage of T-cell receptor αβ variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer 56: 78
96. Stewart MJ, Plautz GE, Del Buono L, Yang ZY, Xu L, Gao X, Huang L, Nabel EG, Nabel GJ (1992) Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 3: 267
97. Tanaka K, Isselbacher KJ, Khoury G, Jay G (1985) Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228: 26
98. Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503
99. Topalian SL, Kasid A, Rosenberg SA (1990) Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures. J Immunol 144: 4487
100. Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CDS+ T cells by B7-transfected melanoma cells. Science 259: 368
101. Van Gool SW, Barcy S, Devos S, Vandenberghe P, Ceuppens JL, Thielemans K, de Boer M (1995) CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy? Res Immunol 146: 183
102. Vogelzang NJ, Lestingi TM, Sudakoff G (1994) Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum Gene Ther 5: 1357
103. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301
104. Wang Z, Cao Y, Albino AP, Zeff AR, Houghton A, Ferrone S (1993) Lack of HLA class I antigen expression by melanoma cells SK-Mel-33 caused by a reading frameshift in β2-microglobulin messenger RNA. J Clin Invest 91: 684
105. Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL (1993) Usage of T-cell receptor Vβ chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer 54: 383
106. Yoshizawa H, Chang AE, Shu S (1991) Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 147: 729
107. Zbar B, Bernstein ID, Rapp HJ (1971) Suppression of tumor growth at the site of infection with living bacillus Calmette-Guerin. J Natl Cancer Inst 46: 831